Corium Announces Publication of Promising Data for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corium Announces Publication of Promising Data for Needle-Free Transdermal Influenza Vaccine

MENLO PARK, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI ), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the publication of promising data on the use of its needle-free transdermal system to deliver influenza vaccine in the June 9, 2015 issue of Vaccine , a pre-eminent publication on vaccines and vaccination. The manuscript, entitled " Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs ," details results of a preclinical study conducted by Novartis Vaccines and Corium. Importantly, the results demonstrate the compatibility of Corium's MicroCor ® needle-free transdermal system with cell culture-derived influenza vaccines, and establish its potential as a next-generation vaccine delivery system.

In the study, trivalent seasonal influenza cell culture-derived antigens were successfully fabricated for in vivo administration using the MicroCor system and resulted in immunization results comparable to the control vaccine delivered by intramuscular injection. In addition, preliminary data related to the incorporation of influenza antigens within the polymer matrix indicate stability of the antigens in the dried state, suggesting potential for longer-term stability at room temperature. Authors of the paper conclude that "taken together, utilization of cell culture-based production of influenza vaccines along with microstructure delivery could potentially change the way vaccines are administered, particularly in the event of a pandemic."

"There is a significant unmet need for improving influenza vaccine accessibility by providing easy to use and needle-free delivery systems," said Parminder "Bobby" Singh, Ph.D., Chief Technology Officer and Vice President, R&D at Corium and a co-author of the paper. "We believe that use of our MicroCor technology to deliver influenza vaccine could provide significant benefit through improved immunization outcomes and more convenient vaccine delivery based on the results of this study."

About the MicroCor ® Transdermal Delivery System

Corium's MicroCor system is a clinical-stage technology utilizing biodegradable microstructures for safe, effective and convenient transdermal delivery of small molecules and biologics, including vaccines, peptides and proteins. The system integrates active agents directly into arrays of solid-state biodegradable microstructures, or "microneedles," that penetrate the outer layers of the skin to release peptides, proteins or vaccines for local or systemic absorption. The solid-state nature of the MicroCor system enables room-temperature stability, simplifying handling, storage and reducing wastage. In addition, there are no needles or sharps left behind after use, providing a safer delivery system for healthcare workers and caregivers. Corium has established GMP manufacturing facilities and quality systems for scale-up, and has developed cost-effective manufacturing processes.

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor ® , a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders. For further information, please visit www.coriumgroup.com .

About Vaccine

Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It is the official journal of The Edward Jenner Society, The International Society for Vaccines and The Japanese Society for Vaccinology and is published by Elsevier. www.elsevier.com/locate/vaccine

Copies of this paper are available to credentialed journalists upon request; please contact Elsevier's Newsroom at newsroom@elsevier.com or +31 20 4853564.

" Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs ," by Amanda Bonificio, Esi Ghartey-Tagoe, Simona Gallorini, Barbara Baudner, Guohua Chen, Parminder Singh, Derek T. O'Hagan, Sushma Kommareddy. DOI: http://dx.doi.org/10.1016/j.vaccine.2015.04.059 . The article appears in Vaccine , Volume 33, Issue 25, pp. 2930-2938, 2015, published by Elsevier.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, clinical trial plans and the advancement of our technologies and our proprietary and partnered products and product candidates. Forward-looking statements are based on management's current expectations and projections and are subject to risks and uncertainties, which may cause Corium's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Corium's business and its financial results are detailed in Corium's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed with the Securities and Exchange Commission on May 8, 2015, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Corium undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Investor and Media Contact: Karen L. Bergman BCC Partners 650-575-1509

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 129

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 21

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 344

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 259

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 378

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 305

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading

Top 5 Most Recently Viewed Articles

Dollar Tree's Earnings Drop and Future Outlook Challenges

Updated Category News Views 123

Highlights from Dollar Tree's Earnings Report Dollar Tree has encountered significant challenges in the market after revealing that its second-quarter earnings did not meet analysts' expectations. The discount retailer reported a year-over-year decline in net income, attributing this downturn to the considerable difficulties posed by the current economic conditions. This...

Continue Reading
The Risks of Banking Standards: A Deep Dive into Safety

Updated Category News Views 411

Understanding Current Banking Risks Banks are integral to the economy, ensuring that funds flow smoothly throughout various sectors. However, recent decisions to relax standards for banks have raised significant concerns about potential risks that may arise. Weiss Ratings, a prominent name in independent bank safety evaluations, has recently highlighted unsettling changes...

Continue Reading
Koch and OCP Forge Ahead with New Joint Venture

Updated Category News Views 46

Tying Two Giants Together When industrial titans like Koch Ag & Energy Solutions and Moroccan powerhouse OCP decide to double down on their existing partnership, anyone with a stake in iron and fertilizer industries ought to take note. It's not every day that two behemoth corporations decide to lace up together in a joint venture, signaling a potential shift in market...

Continue Reading
Youlife Group Inc. Moves to Expand with Strategic Acquisitions

Updated Category News Views 213

Youlife Group Inc. Expands Market Reach with Key Acquisitions Youlife Group Inc. (NASDAQ: YOU), recognized as a leading provider of blue-collar lifetime services, has exciting plans to make strategic acquisitions aimed at bolstering its market position. This initiative comes as Youlife enters into non-binding term sheets with the controlling shareholders of four notable...

Continue Reading
Advancements in Wet AMD Treatment: Outlook Therapeutics Updates

Updated Category News Views 326

Significant Milestones for Outlook Therapeutics ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pioneering biopharmaceutical company, has made notable strides towards securing regulatory approval for its innovative treatment for wet age-related macular degeneration (wet AMD). Their investigational product, ONS-5010 (bevacizumab-vikg), is an ophthalmic...

Continue Reading